Abstract: This application relates to dye-therapeutic moiety conjugates for imaging, targeting, and treating cancerous cells and/or tumors.

Abstract: The present invention generally relates to sensitizer compounds and their use in combination with Tyrosine Kinase Inhibitors (TKIs) for sensitizing tumor, cancer or pre-cancerous cells to TKI treatment. In particular, the present invention relates to administration regimes that combine TKIs such as Gefitinib or Icotinib with TKI-sensitizing DZ1 esters and amides conjugated to statin or platin-based drugs, or to Artemisinin, including, without limitation: DZ1-Simvastatin amide, DZ1-Simvastatin ester, DZ1-Cisplatin ester, and DZ1-Cisplatin amide, DZ1-Artemisinin ester, and DZ1-Artemisinin amide. Furthermore, the present invention relates to improved TKI treatment of cancers by sensitizing tumor, cancer or pre-cancerous cells, in particular cancers that develop TKI resistance, including e.g. lung cancer and pancreatic cancer.

Abstract: The present invention generally relates to sensitizer compounds and their use to sensitize cancer and/or pre-cancerous cells of certain cancers to treatment with certain resistance-prone therapeutics used in cancer therapy. In embodiments, the conjugates of particular esters or amides of Near Infrared Dyes, are used as sensitizers to avoid or overcome therapeutic resistance once formed. In embodiments, the sensitizers include conjugates with Cisplatin, Simvastatin, Artemisinin, platin-based compounds or statins. In embodiments, the resistance prone cancer therapeutics include cisplatin, gemcitabine, doxorubicin, paclitaxel, docetaxel, and platin-based compounds. These may be administered in combination with the sensitizer, or the sensitizer itself may comprise an therapeutic-derived moiety conjugated to the sensitizer, for example as is the case for dye-CIS conjugated sensitizers. Alternatively, the sensitizer may be co-administered with one or more therapeutic.

Abstract: A valance component that includes a first leg, a second leg, a rib extending between an intermediate portion of the first leg to an intermediate portion of the second leg and a member connected to the first and second legs is disclosed. The member has a first face that faces toward the first leg and a second face that faces toward the second leg. The member is sized and configured to be positioned between a valance side and a valance front member, which each have a groove sized to receive at least a portion of the first leg or the second leg. A kit is also disclosed that includes at least one of the valance components, two or more valance side members and at least one valance front member. The kit may include separately packaged components or components that are all retained within one package.

Abstract: A slat for a blind is to be arranged in a plurality in a hollow of a frame of a blind. And at least one of the plural slats is composed of two wooden boards that are respectively provided with a hollow to face each other, and an intermediate layer is sandwiched between the two wooden boards in the hollows. Then the intermediate layer may be made of cloth, unwoven cloth, colored glass, long woven material or the like admitting varying amounts of light. Thus, the intermediate layer can be exposed in the hollows not hidden by the wooden boards, making the blind looking neat and pretty.